Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
about
Multiple myelomaEfficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-AnalysisMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationVenous and arterial thrombotic risks with thalidomide: evidence and practical guidanceCost-effectiveness of bortezomib for multiple myeloma: a systematic reviewEnoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomideAddition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trialAre maintenance and continuous therapies indicated for every patient with multiple myeloma?Older patients with myeloma derive similar benefit from autologous transplantation.Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.Review of health-related quality of life data in multiple myeloma patients treated with novel agents.Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.The clinical safety of lenalidomide in multiple myeloma and myelodysplastic syndromes.Bortezomib: the evidence of its clinical impact in multiple myeloma.Novel therapies in multiple myeloma for newly diagnosed nontransplant candidatesAdverse effects of thalidomide administration, in patients with myeloma multiplex?Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand.Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciencesArterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based studyAnti-angiogenesis therapies: their potential in cancer managementArsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trialMultiple myeloma in the older adult: better prospects, more challenges.Access to thalidomide for the treatment of multiple myeloma in Canada: physician behaviours and ethical implications.Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials.Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agentsThalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses.Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Lenalidomide in the treatment of multiple myeloma: a review.Multiple myeloma presenting as acute renal failureNCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maA combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant-candidate patients with newly diagnosed multiple myeloma.Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.IMWG consensus on maintenance therapy in multiple myeloma.Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.Infections in Hospitalised Patients with Multiple Myeloma: Main Characteristics and Risk Factors
P2860
Q24655964-4E287FAD-2A62-4E01-B8D0-536E7748DB0FQ26767418-E3756918-4294-427B-8352-C94F262ABA80Q26998884-768494E3-8468-4CA0-919C-28A92661FD9FQ27002668-FFE9DEF0-70C2-4505-8609-515C6128FD6EQ27008491-6032F7CD-7576-497C-ADEA-2BB957D7D751Q28075297-B01DF26C-F5B7-4D43-BCFE-E721ECF7431EQ28199907-440189E5-A4A2-4280-B12C-90FD49B2D31FQ28213525-E9909D51-59B8-4041-883D-70612933C3FFQ30249790-187FA39E-0E70-4146-A6B6-68D6DDCA0793Q30370038-ECB86920-7E63-42CD-9896-E8E1E98F67FDQ30595175-00B20948-831C-4ED4-8286-34378B6AC31DQ30650394-AABDF312-29C8-4713-BE06-D2CC5471B0AAQ33387733-705DECCC-EC0D-4D20-8C2D-7BAB4BF5B1D1Q33389075-F3791A0B-1AF8-4C05-BD74-0AC13F918940Q33398044-8F30BF31-63DA-4DBB-AE27-BFD4DF6DBEC2Q33400724-E90E60D8-7614-4F3E-B564-26B9563B7852Q33639796-C08764C2-F0A5-44E5-8D4F-7513243DD420Q33669639-3833656A-6E61-49EC-8CA6-97841C1DD6E9Q33687489-38C6C4C3-6156-4A86-B8BF-66D8B1779B2DQ33710994-496934D4-0C48-4B72-A72F-A17A60B8FCB1Q33931754-0D46D699-D3D8-4964-A55C-2F5AC90EE7D9Q33956056-EBE40FB8-F161-4C80-B1B3-55CD35F3FCD9Q33956059-B9C30D6C-DD39-4A79-9B34-9D51883EE988Q34031129-50BB0612-6F30-4D3C-B6B2-0E37D5AAE6E9Q34035424-0A3655DE-3E62-4075-BE09-095604015534Q34253548-075D506B-B5AE-4D69-A395-F4E905267A7DQ34372086-43AA0366-1FFB-4D5C-B61D-77CF00B1C1BAQ34451635-76D424D5-2801-4F07-ACE2-F056ADA06006Q34586861-009240E1-617D-4289-A15E-ACEDE76AF0AAQ34604658-6356D4AF-3DE3-47A0-9045-CDD4A016B1FBQ34775475-CA675E6F-0CCA-4D7D-8F66-FF35ABE69E10Q34775515-4F4FB5F3-61AE-47A3-B0BE-88BE8F1DFA7AQ35488351-1B1E02B8-4512-4093-8E51-B1DDC11E492DQ35605318-BB5ACA25-8F35-4987-A84F-8AD76EED459CQ35631904-C6DC7518-AE81-45AB-BE15-F20E4EFA2EFFQ35669893-9F2DA1DC-1ECA-4F30-A77C-5C0814A1411CQ35675837-9C45A8A0-0DAC-4BD2-BB19-3201BFDED9F6Q35876966-9B9436B0-DB6D-47AA-9CB8-7FA678AC11F9Q35932505-53B812B0-E612-4F1E-9F81-E3022746949EQ36038899-B12E22FC-0F6B-4622-AF2E-5031A524FEAF
P2860
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Oral melphalan and prednisone ...... : randomised controlled trial.
@en
Oral melphalan and prednisone ...... : randomised controlled trial.
@nl
type
label
Oral melphalan and prednisone ...... : randomised controlled trial.
@en
Oral melphalan and prednisone ...... : randomised controlled trial.
@nl
prefLabel
Oral melphalan and prednisone ...... : randomised controlled trial.
@en
Oral melphalan and prednisone ...... : randomised controlled trial.
@nl
P2093
P50
P921
P1433
P1476
Oral melphalan and prednisone ...... : randomised controlled trial.
@en
P2093
Anna Marina Liberati
Clotilde Cangialosi
Elena Zamagni
Emanuela Merla
Fausto Rossini
Ilaria Avonto
Italian Multiple Myeloma Network, GIMEMA
Lucio Catalano
Maria Teresa Ambrosini
Maria Teresa Petrucci
P304
P356
10.1016/S0140-6736(06)68338-4
P407
P577
2006-03-01T00:00:00Z